- Seattle, Washington
- Juno Therapeutics, a clinical-stage company, develops immunotherapies for the treatment of cancer.
- Isabelle Rivière, Renier Brentjens, Michel Sadelain, Phil Greenberg, Stan Riddell, Michael Jensen
- Therapeutics, Health Care, Biotechnology
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
Funding Rounds (3) - $310MUpdate
Current Team (8)Update
307 Westlake Avenue North
Seattle, Washington 98109